ALOX15 and colitis: In the DSS colitis model we found that Alox15-KI mice were protected from the development of inflammatory symptoms as indicated by the differential body weight kinetics (Fig. 2A), by the degree of colon shortening (Fig. 2B), by quantification of histological inflammation markers (Fig. 2C) and by the expression profiles of pro-inflammatory gene products (Fig. 2D–F).